the safety and efficacy evaluation of Anti-HPV Biological protein Contact film for the treatment of high risk HPV

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002017

Enrollment

Unknown

Registered

2012-03-08

Start date

2012-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPVHigh risk HPV

Interventions

Control group:Blank control

Test group:Anti HPV biological protein contact film

Eligibility

Sex/Gender

Female

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 30-65years old, female. Subjects were diagnosed at high risk of HPV positive.

Exclusion criteria

Exclusion criteria: 1. Except Menstrual period, pregnancy and lactation period, 2. The Subjects should excepted the high-grade cervical lesions; 3. There are known to be associated with the constituents of a history of allergy; 4. Liver function and renal function abnormalities; 5. Suspected or diagnosed with malignant tumors; 6. Immunocompromised persons; 7. Inflammation of the vagina (Trichomonas, mildew, bacteria) treatment of the original diseases before entering the group; 8. Sexually transmitted disease; 9. The doctor based on clinical experience that are not suitable for selected patients.

Design outcomes

Primary

Measure	Time frame
negative conversion rate of HPV;	—

Countries

China

Contacts

Public ContactXia Yang

yang-xia1974@163.com+86 13663512021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026